ARAF is altered in 1.6% of malignant solid tumor patients [3].

ARAF is an inclusion criterion in 17 clinical trials for malignant solid tumor, of which 14 are open and 3 are closed. Of the trials that contain ARAF status and malignant solid tumor as inclusion criteria, 10 are phase 1 (9 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (3 open) [4].

ARAF is altered in 1.87% of non-small cell lung carcinoma patients [3].

ARAF is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 7 are open and 1 is closed. Of the trials that contain ARAF status and non-small cell lung carcinoma as inclusion criteria, 6 are phase 1 (6 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

ARAF is altered in 2.42% of melanoma patients [3].

ARAF is an inclusion criterion in 5 clinical trials for melanoma, of which 5 are open and 0 are closed. Of the trials that contain ARAF status and melanoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 1/phase 2 (2 open) [4].

ARAF is altered in 0.79% of non-hodgkin lymphoma patients [3].

ARAF is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ARAF status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [4].

ARAF is altered in 2.2% of colorectal carcinoma patients [3].

ARAF is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARAF status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 1.57% of histiocytic and dendritic cell neoplasm patients [3].

ARAF is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain ARAF status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [4].

ARAF is altered in 2.48% of ovarian carcinoma patients [3].

ARAF is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARAF status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 1.08% of glioma patients [3].

ARAF is an inclusion criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain ARAF status and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

ARAF is altered in 0.9% of low grade glioma patients [3].

ARAF is an inclusion criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain ARAF status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 0.51% of thyroid gland carcinoma patients [3].

ARAF is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARAF status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

ARAF is altered in 5.05% of endometrial carcinoma patients [3].

ARAF is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 3.03% of pancreatic ductal adenocarcinoma patients [3].

ARAF is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ARAF is altered in 2.52% of cutaneous melanoma patients [3].

ARAF is an inclusion criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ARAF is altered in 1.49% of schwannoma patients [3].

ARAF is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 1.89% of squamous cell lung carcinoma patients [3].

ARAF is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 1.19% of ganglioglioma patients [3].

ARAF is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 1.29% of diffuse glioma patients [3].

ARAF is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 1.42% of hepatocellular carcinoma patients [3].

ARAF is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARAF is altered in 3.49% of malignant peripheral nerve sheath tumor patients [3].

ARAF is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 1.13% of astrocytic tumor patients [3].

ARAF is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 0.82% of neuroblastoma patients [3].

ARAF is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 1.09% of breast carcinoma patients [3].

ARAF is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 0.61% of neuronal and mixed neuronal-glial tumors patients [3].

ARAF is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 0.87% of soft tissue sarcoma patients [3].

ARAF is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 0.44% of renal cell carcinoma patients [3].

ARAF is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 0.4% of pancreatic carcinoma patients [3].

ARAF is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is altered in 0.17% of acute myeloid leukemia patients [3].

ARAF is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ARAF is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

ARAF is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [4].

ARAF is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [4].

ARAF is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [4].

ARAF is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARAF is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARAF is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].